Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Humacyte (HUMA – Research Report) today and set a price target of $17.00.
Bruce Jackson’s rating is based on Humacyte’s promising developments and strategic collaborations that suggest strong future potential. The company recently hosted an event with key opinion leaders, where vascular surgeons expressed optimism about Humacyte’s Symvess product. The retrospective comparison study indicated that Symvess could perform similarly to the current standard, autologous vein, in treating extremity arterial injuries, which could lead to its increased adoption in the market.
Additionally, Humacyte’s collaboration with Trestle Bio to explore bioengineered kidney tissues for end-stage renal disease patients highlights the company’s innovative approach and potential for growth in the bioengineering sector. The ongoing early launch activities, including the initiation of the VAC process in more hospitals, and the publication of a budget impact model in a medical journal, further bolster the company’s market position and sales prospects.
In another report released on February 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com